AbbVie Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
| Page | |
|---|---|
| Consolidated Financial Statements | |
| Consolidated Statements of Earnings | 51 |
| Consolidated Statements of Comprehensive Income | 52 |
| Consolidated Balance Sheets | 53 |
| Consolidated Statements of Equity | 54 |
| Consolidated Statements of Cash Flows | 55 |
Notes to Consolidated Financial Statements
| Note 1 | Background | 56 |
|---|---|---|
| Note 2 | Summary of Significant Accounting Policies | 56 |
| Note 3 | Supplemental Financial Information | 61 |
| Note 4 | Earnings Per Share | 62 |
| Note 5 | Licensing, Acquisitions and Other Arrangements | 62 |
| Note 6 | Collaborations | 65 |
| Note 7 | Goodwill and Intangible Assets | 66 |
| Note 8 | Integration and Restructuring Plans | 67 |
| Note 9 | Leases | 69 |
| Note 10 | Debit, Credit Facilities and Commitments and Contingencies | 71 |
| Note 11 | Financial Instruments and Fair Value Measures | 73 |
| Note 12 | Post-Employment Benefits | 79 |
| Note 13 | Equity | 83 |
| Note 14 | Income Taxes | 88 |
| Note 15 | Legal Proceedings and Contingencies | 90 |
| Note 16 | Segment and Geographic Area Information | 92 |
| Note 17 | Fourth Quarter Financial Results (unaudited) | 95 |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 96 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.